Phase 1b/2 study of rebastinib (DCC-2036) in combination with paclitaxel: Preliminary safety, efficacy, pharmacokinetics and pharmacodynamics in patients with advanced or metastatic solid tumors

被引：2
|
作者：
Janku, Filip [1 ]
Birrer, Michael [2 ]
Richardson, Debra [3 ]
Chu, Christina [4 ]
Goel, Sanjay [5 ]
Su, Ying [6 ]
Matin, Bahar [6 ]
Kuida, Keisuke [6 ]
Ruiz-Soto, Rodrigo [6 ]
Hamilton, Erika Paige [7 ,8 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Alabama Birmingham, Birmingham Comprehens Canc Ctr, Birmingham, AL USA
[3] Univ Oklahoma, Hlth Sci Ctr, Stephenson Canc Ctr, Sarah Cannon Res Inst, Oklahoma City, OK USA
[4] Fox Chase Canc Ctr, Havertown, PA USA
[5] Albert Einstein Coll Med, Bronx, NY 10467 USA
[6] Deciphera Pharmaceut LLC, Waltham, MA USA
[7] Sarah Cannon Res Inst, Nashville, TN USA
[8] Tennessee Oncol PLLC, Nashville, TN USA
来源：
MOLECULAR CANCER THERAPEUTICS | 2019年 / 18卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-19-B055
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B055
引用
收藏
页数：3
相关论文
共 50 条
  • [1] An open label, multicenter, phase 1 b/2 study of rebastinib (DCC-2036) in combination with carboplatin to assess safety, tolerability, and pharmacokinetics in patients with advanced or metastatic solid tumors.
    Tolcher, Anthony W.
    Munster, Pamela N.
    Rosen, Lee S.
    Murphy, Curran
    Argueta, Christian
    Kuida, Keisuke
    Ruiz-Soto, Rodrigo
    Janku, Filip
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [2] Open-label, multicenter, phase 1b/2 study of rebastinib in combination with paclitaxel to assess safety and efficacy in patients with advanced or metastatic endometrial cancer.
    Janku, Filip
    Hamilton, Erika P.
    Mathews, Cara Amanda
    Chu, Christina
    Diamond, Jennifer Robinson
    Hays, John L.
    Arend, Rebecca Christian
    Cristofanilli, Massimo
    Jewell, Andrea
    Reichmann, William
    Kuida, Keisuke
    Achour, Haroun
    Ruiz-Soto, Rodrigo
    Richardson, Debra L.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [3] A phase 1b study evaluating the safety and pharmacokinetics of regorafenib in combination with cetuximab in patients with advanced solid tumors
    Weekes, Colin
    Lockhart, A. Craig
    Lee, James J.
    Sturm, Isrid
    Cleton, Adriaan
    Huang, Funan
    Lenz, Heinz-Josef
    INTERNATIONAL JOURNAL OF CANCER, 2019, 145 (09) : 2450 - 2458
  • [4] A phase 1b study of the safety, pharmacokinetics, and preliminary antitumor activity of citarinostat (ACY-241) in combination with paclitaxel (Pac) in patients (pts) with advanced solid tumors (AST).
    Gordon, Michael S.
    Shapiro, Geoffrey
    Sarantopoulos, John
    Juric, Dejan
    Lu, Brian
    Chen, Peng
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] Phase 1 study of safety, pharmacokinetics, and pharmacodynamics of tivantinib in combination with bevacizumab in adult patients with advanced solid tumors
    Maguire, William F.
    Schmitz, John C.
    Scemama, Jonas
    Czambel, Ken
    Lin, Yan
    Green, Anthony G.
    Wu, Shaoyu
    Lin, Huang
    Puhalla, Shannon
    Rhee, John
    Stoller, Ronald
    Tawbi, Hussein
    Lee, James J.
    Wright, John J.
    Beumer, Jan H.
    Chu, Edward
    Appleman, Leonard J.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 88 (04) : 643 - 654
  • [6] Phase 1 study of safety, pharmacokinetics, and pharmacodynamics of tivantinib in combination with bevacizumab in adult patients with advanced solid tumors
    William F. Maguire
    John C. Schmitz
    Jonas Scemama
    Ken Czambel
    Yan Lin
    Anthony G. Green
    Shaoyu Wu
    Huang Lin
    Shannon Puhalla
    John Rhee
    Ronald Stoller
    Hussein Tawbi
    James J. Lee
    John J. Wright
    Jan H. Beumer
    Edward Chu
    Leonard J. Appleman
    Cancer Chemotherapy and Pharmacology, 2021, 88 : 643 - 654
  • [7] Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia
    Cortes, Jorge
    Talpaz, Moshe
    Smith, Hedy P.
    Snyder, David S.
    Khoury, Jean
    Bhalla, Kapil N.
    Pinilla-Ibarz, Javier
    Larson, Richard
    Mitchell, David
    Wise, Scott C.
    Rutkoski, Thomas J.
    Smith, Bryan D.
    Flynn, Daniel L.
    Kantarjian, Hagop M.
    Rosen, Oliver
    Van Etten, Richard A.
    HAEMATOLOGICA, 2017, 102 (03) : 519 - 528
  • [8] A phase 1b/2 study of ramucirumab in combination with emibetuzumab in patients with advanced solid tumors
    Bendell, Johanna
    Fuchs, Charles
    Voss, Martin
    Bauer, Todd M.
    Choueiri, Toni K.
    Drilon, Alexander
    Thorn, Katharine
    Wijayawardana, Sameera
    Moser, Brian
    Urunuela, Arantxa
    Wacheck, Volker
    Harding, James J.
    CANCER RESEARCH, 2017, 77
  • [9] A phase 1b study evaluating the safety and pharmacokinetics (PK) of regorafenib (REG) in combination with cetuximab (CTX) in patients with advanced solid tumors
    Weekes, C.
    Lockhart, A. C.
    Lenz, H-J.
    Lee, J. J.
    Cleton, A.
    Huang, F.
    Sturm, I.
    ANNALS OF ONCOLOGY, 2017, 28
  • [10] Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study
    Kotasek, Dusan
    Tebbutt, Niall
    Desai, Jayesh
    Welch, Stephen
    Siu, Lillian L.
    McCoy, Sheryl
    Sun, Yu-Nien
    Johnson, Jessica
    Adewoye, Adeboye H.
    Price, Timothy
    BMC CANCER, 2011, 11
12345